Literature DB >> 23335604

Impact of tricuspid regurgitation on survival in patients with chronic heart failure: unexpected findings of a long-term observational study.

Stephanie Neuhold1, Martin Huelsmann, Elisabeth Pernicka, Alexandra Graf, Diana Bonderman, Christopher Adlbrecht, Thomas Binder, Gerald Maurer, Richard Pacher, Julia Mascherbauer.   

Abstract

AIMS: Tricuspid regurgitation (TR) is common in patients with chronic heart failure (CHF) but its prognostic impact is unclear. METHODS AND
RESULTS: A total of 576 consecutive patients with CHF were prospectively included. The impact of moderate and severe (significant) TR on the combined endpoint death/heart transplantation/left ventricular-assist device implantation was assessed. Patients were followed for 5.8 ± 4.2 (maximum 14.4) years. Kaplan-Meier analysis showed a worse outcome of patients with significant TR (P < 0.0001). By multivariable analysis, amino terminal pro B-type natriuretic peptide (NT-proBNP) (P = 0.0028), systolic left ventricular function (LVF) (P = 0.0014), serum sodium, NYHA functional class, systolic blood pressure, right atrial size (all P = 0.0001), but not TR were significantly related with the outcome. However, as soon as the strong interaction between TR and LVF was included in the model, significant TR determined outcome as well (P = 0.0059). Therefore, in a second analysis patients were stratified for LVF. In patients with mildly or moderately impaired LVF, TR was significantly related with the outcome (HR: 1.368, CI: 1.070-1.748, P = 0.0125), whereas in patients with severely depressed LVF it was not (P = 0.1401). As a proof of concept, we additionally stratified patients according to serum NT-proBNP concentrations. In patients with NT-proBNP concentrations below the median (≤ 280 fmol/mL), TR was related with the outcome (HR: 2.512, CI: 1.127-5.597, P = 0.0242) but it was not in patients with NT-proBNP concentrations above the median (P = 0.3935).
CONCLUSION: The prognostic impact of TR depends on the severity of CHF. While TR was significantly related with excess mortality in mild to moderate CHF, it provided no additive value in advanced disease when compared with established risk factors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23335604     DOI: 10.1093/eurheartj/ehs465

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  23 in total

1.  The impact of tricuspid annular geometry on outcome after percutaneous edge-to-edge repair for severe tricuspid regurgitation.

Authors:  Sylvia Otto; Marija Velichkov; Ali Hamadanchi; P Christian Schulze; Sven Moebius-Winkler
Journal:  Cardiol J       Date:  2021-05-04       Impact factor: 2.737

Review 2.  [Current technologies in interventional treatment of tricuspid valve regurgitation].

Authors:  Sebastian Rosch; Philipp Lurz
Journal:  Herz       Date:  2021-08-10       Impact factor: 1.443

Review 3.  [Medicinal treatment of tricuspid valve regurgitation].

Authors:  M Lankeit; K Keller; C Tschöpe; B Pieske
Journal:  Herz       Date:  2017-11       Impact factor: 1.443

4.  Interventional treatment of tricuspid regurgitation : An important innovation in cardiology.

Authors:  Georg Goliasch; Julia Mascherbauer
Journal:  Wien Klin Wochenschr       Date:  2020-02       Impact factor: 1.704

Review 5.  [MitraClip® for treatment of tricuspid valve insufficiency].

Authors:  R Pfister; S Baldus
Journal:  Herz       Date:  2017-11       Impact factor: 1.443

6.  Right heart chamber geometry and tricuspid annulus morphology in patients undergoing mitral valve repair with and without tricuspid valve annuloplasty.

Authors:  Gloria Tamborini; Laura Fusini; Manuela Muratori; Paola Gripari; Sarah Ghulam Ali; Cesare Fiorentini; Mauro Pepi
Journal:  Int J Cardiovasc Imaging       Date:  2016-01-28       Impact factor: 2.357

Review 7.  Tricuspid valve disease: diagnosis, prognosis and management of a rapidly evolving field.

Authors:  Lluis Asmarats; Maurizio Taramasso; Josep Rodés-Cabau
Journal:  Nat Rev Cardiol       Date:  2019-09       Impact factor: 32.419

8.  Prognostic Impact of Tricuspid Regurgitation in Patients Undergoing Aortic Valve Surgery for Aortic Stenosis.

Authors:  Julia Mascherbauer; Andreas A Kammerlander; Beatrice A Marzluf; Alexandra Graf; Alfred Kocher; Diana Bonderman
Journal:  PLoS One       Date:  2015-08-20       Impact factor: 3.240

9.  Contemporary Trends in the Use and Outcomes of Surgical Treatment of Tricuspid Regurgitation.

Authors:  Fahad Alqahtani; Chalak O Berzingi; Sami Aljohani; Mohamad Hijazi; Ahmad Al-Hallak; Mohamad Alkhouli
Journal:  J Am Heart Assoc       Date:  2017-12-22       Impact factor: 5.501

10.  Clinical outcomes of conventional surgery versus MitraClip® therapy for moderate to severe symptomatic mitral valve regurgitation in the elderly population: an institutional experience.

Authors:  Anthony Alozie; Liliya Paranskaya; Bernd Westphal; Alexander Kaminski; Mohammad Sherif; Magnus Sindt; Stephan Kische; Jochen Schubert; Doreen Diedrich; Hüseyin Ince; Gustav Steinhoff; Alper Öner
Journal:  BMC Cardiovasc Disord       Date:  2017-03-20       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.